The next step towards changing treatment paradigms in immuno-oncology
The current revolution in immuno-oncology is being driven by Antibody Drug Conjugates, Immune Checkpoint Inhibitors, Bispecific Antibodies and Cell Therapies. Clinical trials have showed that cancer patients can tolerate this immune-based treatment more effectively than conventional treatments like chemotherapy and radiotherapy. It’s clearly one of the hottest fields of Biopharma which has gained momentum in the past few years.
With more than 45 speakers across the world from pharma, bio-pharma and biotech companies, the congress will discuss the latest updates in development of ADC’s, Monoclonal Antibodies, Bispecific Antibodies, Immune Checkpoint Inhibitors and Cellular Therapy
Meet and network with experts from leading universities and industry sharing their knowledge on Preclinical and Translational Immuno-Oncology Developments, Next Gen CAR-T Cell Therapy, Immune Checkpoint Inhibitors, Monoclonal and Bispecific Antibodies and more.
A platform to meet experts from Pharma, bio-pharma and biotech companies and increase your learning in Monoclonal and Bispecific Antibodies, Cell Therapy and Immune Checkpoint Inhibitors.
After our successful edition last year, we are coming up with the “2nd Annual MarketsandMarkets Next-Gen Immuno-Oncology Congress” on 19-20 September, Philadelphia, USA which will gather academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to discuss the latest updates in development of ADC’s, Monoclonal Antibodies, Bispecific Antibodies, Immune Checkpoint Inhibitors and Cellular Therapy.
